Spok Holdings, Inc. (SPOK)
NASDAQ: SPOK · IEX Real-Time Price · USD
15.27
+0.35 (2.35%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Spok Holdings Revenue
Spok Holdings had revenue of $140.75M in the twelve months ending March 31, 2024, with 5.13% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $34.91M with 5.21% year-over-year growth. In the year 2023, Spok Holdings had annual revenue of $139.03M with 3.34% growth.
Revenue (ttm)
$140.75M
Revenue Growth
+5.13%
P/S Ratio
2.20
Revenue / Employee
$359,064
Employees
392
Market Cap
309.15M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 139.03M | 4.49M | 3.34% |
Dec 31, 2022 | 134.53M | -7.62M | -5.36% |
Dec 31, 2021 | 142.15M | -6.03M | -4.07% |
Dec 31, 2020 | 148.18M | -12.11M | -7.55% |
Dec 31, 2019 | 160.29M | -9.19M | -5.42% |
Dec 31, 2018 | 169.47M | -1.70M | -0.99% |
Dec 31, 2017 | 171.18M | -8.39M | -4.67% |
Dec 31, 2016 | 179.56M | -10.07M | -5.31% |
Dec 31, 2015 | 189.63M | -10.65M | -5.32% |
Dec 31, 2014 | 200.27M | -9.48M | -4.52% |
Dec 31, 2013 | 209.75M | -9.94M | -4.53% |
Dec 31, 2012 | 219.70M | -14.00M | -5.99% |
Dec 31, 2011 | 233.69M | 439.00K | 0.19% |
Dec 31, 2010 | 233.25M | -56.45M | -19.49% |
Dec 31, 2009 | 289.71M | -69.74M | -19.40% |
Dec 31, 2008 | 359.45M | -65.18M | -15.35% |
Dec 31, 2007 | 424.62M | -73.07M | -14.68% |
Dec 31, 2006 | 497.69M | -120.88M | -19.54% |
Dec 31, 2005 | 618.57M | 128.41M | 26.20% |
Dec 31, 2004 | 490.16M | -107.32M | -17.96% |
Dec 31, 2003 | 597.48M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nevro | 430.75M |
Cerus | 191.72M |
Vanda Pharmaceuticals | 177.60M |
Xeris Biopharma Holdings | 171.36M |
AxoGen | 163.73M |
Sight Sciences | 81.50M |
C4 Therapeutics | 20.04M |
Verrica Pharmaceuticals | 8.91M |
SPOK News
- 2 months ago - Spok Reports First Quarter 2024 Results - Business Wire
- 2 months ago - Spok Sets Date to Report First Quarter 2024 Results - Business Wire
- 3 months ago - Spok Achieves Top Client Satisfaction Scores for Seventh Consecutive Year - Business Wire
- 4 months ago - Spok to Present at Sidoti Virtual Investor Conference - Business Wire
- 4 months ago - Spok Reports Fourth Quarter And Full Year 2023 Results - Business Wire
- 4 months ago - Spok Sets Date to Report Fourth Quarter and Full Year 2023 Results - Business Wire
- 8 months ago - Spok to Present and Host 1x1 Investor Meetings at the 35th Annual Piper Sandler & Co. Healthcare Conference - Business Wire
- 8 months ago - Spok Reports Third Quarter 2023 Results - Business Wire